Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

104.83 +0.20 (+0.19%)
Official Closing Price Updated: 5:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Which S&P500 stocks are moving on Tuesday? ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses
The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗
Via MarketBeat
Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗
Via Stocktwits
News headline image
Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? ↗
Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%. 
Via Benzinga
News headline image
Which S&P500 stocks have an unusual volume on Tuesday? ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition ↗
Merck's Winrevair drug achieved its primary goal in the Phase 2 CADENCE study for combined post- and pre-capillary pulmonary hypertension due to HFpEF. 
Via Benzinga
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Merck Announces First-Quarter 2026 Dividend
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go ↗
Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension. 
Via Investor's Business Daily
Topics Government
News headline image
Top S&P500 movers in Tuesday's pre-market session ↗
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
From Merck & Co., Inc.
Via Business Wire
News headline image
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
News headline image
Market Grapples with Valuation Fears Amidst Accelerating Sector Rotation
As November 2025 unfolds, the global financial markets find themselves at a critical juncture, characterized by a palpable sense of unease over elevated valuations in specific sectors and a pronounced... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗
 
Via Benzinga
News headline image
MERCK & CO. INC. (NYSE:MRK): A Value Investment with Strong Fundamentals ↗
Discover Merck (MRK), a top value stock with a low P/E ratio, strong profitability, and solid financial health, offering a potential margin of safety. 
Via Chartmill
News headline image
These 2 Dividend ETFs Are a Retiree's Best Friend ↗
Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This... 
Via TokenRing AI
Topics Artificial Intelligence Economy Product Recall
News headline image
AI and Digital Twins Ignite a New Era of Accelerated Drug Discovery and Development
The pharmaceutical industry is on the cusp of a profound transformation, driven by the synergistic power of artificial intelligence (AI) and digital twins. These cutting-edge technologies are rapidly... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal ↗
The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu. 
Via Investor's Business Daily
News headline image
Merck Makes Big Bet On Flu Protection With Cidara Buyout ↗
Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388. 
Via Benzinga
News headline image
Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio ↗
With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications. 
Via Stocktwits
Topics Intellectual Property
News headline image
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
From Merck & Co., Inc.
Via Business Wire
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗
Via Stocktwits
News headline image
Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference in London
From Merck & Co., Inc.
Via Business Wire
News headline image
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? ↗
Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.